U.S. Markets closed
  • S&P Futures

    3,805.50
    -11.25 (-0.29%)
     
  • Dow Futures

    31,185.00
    -51.00 (-0.16%)
     
  • Nasdaq Futures

    12,621.50
    -60.25 (-0.48%)
     
  • Russell 2000 Futures

    2,195.00
    -10.80 (-0.49%)
     
  • Crude Oil

    61.17
    -0.11 (-0.18%)
     
  • Gold

    1,712.50
    -3.30 (-0.19%)
     
  • Silver

    26.25
    -0.14 (-0.52%)
     
  • EUR/USD

    1.2055
    -0.0012 (-0.0964%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • Vix

    26.67
    +2.57 (+10.66%)
     
  • GBP/USD

    1.3936
    -0.0017 (-0.1185%)
     
  • USD/JPY

    107.0700
    +0.0680 (+0.0636%)
     
  • BTC-USD

    51,561.80
    +2,806.76 (+5.76%)
     
  • CMC Crypto 200

    1,030.19
    +42.10 (+4.26%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,113.28
    -445.82 (-1.51%)
     

Kindred Biosciences to Present at the BofA Securities Animal Health Virtual Summit

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SAN FRANCISCO, Feb. 16, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities Animal Health Virtual Summit on February 25.

Kindred Biosciences, Inc. Logo
Kindred Biosciences, Inc. Logo

Dr. Richard Chin, Chief Executive Officer, will present via webcast at 10.50am ET and be available for virtual one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, study results from key therapeutic programs in development, and upcoming milestones.

An archived version of the above webcast will be available for 30 days on the KindredBio website.

About Kindred Biosciences

Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.

For more information, visit: www.kindredbio.com

Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-present-at-the-bofa-securities-animal-health-virtual-summit-301229317.html

SOURCE Kindred Biosciences, Inc.